Skip to main content
. 2021 Mar 2;118:154739. doi: 10.1016/j.metabol.2021.154739

Fig. 2.

Fig. 2

The serum metabolome of COVID-19 patients is distinct from COVID-19-like patients and HCs. (A) OPLS-DA shows that the metabolome profiles of the COVID-19 patients (n = 30), COVID-19-like patients (n = 15) and HCs (n = 30) are clearly separated from each other in the discovery cohort. (B) OPLS-DA illustrates that the metabolome profiles of the COVID-19 patients (n = 30), COVID-19-like patients (n = 15) and HCs (n = 30) are clearly separated from each other in the validation cohort. (C) Twenty-six metabolites were significantly altered between at least two groups of COVID-19 patients (n = 60), COVID-19-like patients (n = 30) and HCs (n = 60) in the discovery and validation cohorts. Metabolites are marked in red when there is a significant difference in metabolites in the COVID-19 group compared to either of the two other groups in the discovery and validation cohorts. * and # indicate significance when comparing between two groups and “&” indicates significance in comparisons between three groups. *, P < 0.05; **, P < 0.01; ***, P < 0.001 in the discovery cohort; #, P < 0.05; ##, P < 0.01; ###, P < 0.001 in the validation cohort. &, P < 0.05; &&, P < 0.01; &&&, P < 0.001 between the three groups.